Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Suven Pharmaceuticals Limited specializes in the development and manufacturing of specialty pharmaceuticals, particularly in the CNS (central nervous system) segment, with a strong portfolio of products targeting neurological disorders. The company operates primarily in India and has been expanding its presence in international markets, leveraging its proprietary technologies and R&D capabilities.
Suven generates revenue through the sale of proprietary CNS drugs and generic formulations, benefiting from high gross margins due to its focus on niche therapeutic areas. The company has a competitive advantage through its strong R&D pipeline and established relationships with global pharmaceutical firms for contract manufacturing.
Regulatory approvals for new CNS therapies
Market penetration in international markets, particularly the US and Europe
Partnerships or collaborations with major pharmaceutical companies
Changes in pricing regulations for generic drugs
Potential regulatory changes impacting drug approvals and pricing
Technological disruption in drug development processes
Increased competition from generic drug manufacturers
Emerging biotech firms with innovative CNS therapies
Low ROE indicates potential inefficiencies in capital utilization
Rising R&D costs could pressure margins if not managed effectively
moderate - The demand for pharmaceuticals is generally stable, but economic downturns can affect healthcare spending and reimbursement rates.
Low - Suven's low debt levels minimize the impact of rising interest rates on financing costs, but higher rates could dampen overall market demand.
minimal - The company's low debt-to-equity ratio indicates limited reliance on credit markets.
growth - Investors are likely attracted to Suven's potential for high growth in specialty pharmaceuticals, especially in CNS.
moderate - The stock has shown volatility, influenced by regulatory news and market conditions.